Keywords: Eisai, R&D subsidiary, H3 Biomedicine, Cancer drugs, Funding
Japan’s Eisai establishes new US R&D subsidiary to focus on oncology
Article | 31 January 2011
Japanese drug major Eisai (TYO: 4523) says it has established a new R&D subsidiary, called H3 Biomedicine, in Cambridge, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
